PharmaVOICE magazine cites Dr. Lanza for "Courage Under Fire”
WORCESTER, Massachusetts -- Advanced Cell Technology, Inc. (OTCBB:ACTC - News) is proud to announce that Dr. Robert Lanza, the company's Vice President of Research and Scientific Development, has been recognized for his research and contributions to stem cell science and technology in the current issue of PharmaVOICE (cover story July/August issue). Dr. Lanza is one of only five researchers and scientists to be acknowledged for his discoveries "behind the medicines making a significant impact on the pipelines of today and of the future.”
"Though his work has sometimes been attacked by political and religious establishments, Robert Lanza, M.D., forges ahead with research based on the right thing to do scientifically,” PharmaVOICE stated. "Dr. Lanza is boldly leading Advanced Cell Technology's team of scientists toward bringing the benefits of human embryonic stem cell (hESC) technology to the tens of millions of people worldwide who are suffering from a host of degenerative diseases and other conditions,” the journal continued. "Committed to the science, Dr. Lanza believes treatments using hESCs have the potential to eventually offer not just treatments, but actual cures for Parkinson's disease, macular degeneration, heart disease, and a whole host of other debilitating diseases…. Inspired by enlightened thinkers and human kindness, Dr. Lanza believes in the mission of advancing research, and he is looking forward to the next goal: to start human clinical trials using embryonic stem cells.”
"We are pleased that highly regarded journals such as PharmaVOICE continue to recognize the contributions and achievements of our researchers,” remarked William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "Moreover, we are excited by the novel therapies our research may yield to treat indications that have few alternatives.”
Over the past year, Advanced Cell Technology has made significant progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs to treat degenerative retinal disorders and cardiovascular disease, and expects to file INDs for both programs by the end of 2008. Furthermore, the company announced last month that it had entered into a definitive merger agreement to acquire autologous adult stem cell company Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. Mytogen has successfully completed Phase I clinical trials and will begin Phase II trials after the merger with ACT. Upon the transaction's closing, Advanced Cell Technology will transition from a development stage to a clinical stage company.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, visit "www.advancedcell.com":http://www.advancedcell.com
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Chad Griffin Consulting, Inc.